Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 890-895

  Raj, Kavita ^a,b   Pagliuca, Antonio ^a,b,c   Bradstock, Kenneth ^d   Noriega, Victor ^b   Potter, Victoria ^b   Streetly, Matthew ^a,b   Mclornan, Donal ^a,b   Kazmi, Majid ^a,b   Marsh, Judith ^b,c   Kwan, John ^d   Huang, Gillian ^d   Getzendaner, Lisa ^e   Lee, Stephanie ^e,f   Guthrie, Katherine A ^e   Mufti, Ghulam J ^b,c   O'Donnell, Paul ^e,f  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d WESTMEAD HOSPITAL   (Australia)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Haploidentical; Peripheral blood stem cell; Stem cell transplantation

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL; OVERALL SURVIVAL; PATIENT SAFETY; REDUCED INTENSITY CONDITIONING; RELAPSE; T LYMPHOCYTE; THROMBOCYTE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DONOR; HAPLOIDY; HEMATOLOGIC DISEASES; HISTOCOMPATIBILITY; MIDDLE AGED; PROCEDURES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HAPLOIDY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84899960100     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.003     Document Type: Article

References (22)

1. Switzer G.E., Bruce J.G., Myaskovsky L., et al. Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood 2013, 121:1469-1476.
2. Pidala J., Kim J., Schell M., et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and the likelihood of subsequent transplant utilization. Bone Marrow Transplant 2012, 48:346-350.
3. O'Donnell P.V., Luznik L., Jones R.J., et al. Non myeloablative bone marrow transplantation from partially HLA-mismatched related donors using post transplantation cyclophosphamide. Biol Blood and Marrow Transplant 2002, 8:377-386.
4. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood and Marrow Transplant 2008, 14:641-650.
5. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
6. Baldomero H., Gratwohl M., Gratwohl A., et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011, 46:485-501.
7. Allogeneic peripheral blood-stem cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
8. Mielcarek M., Strorer B., Martin P., et al. Long term outcomes after transplantation of HLA-identical related G-CSF mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012, 119:2675-2678.
9. Hassan H.T., Stockschlader M., Schleimer B., et al. Comparison of the content and subpopulations of CD3- and CD34- positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl Immunol 1996, 4:319-323.
10. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
11. Flowers M.E.D., Parker P.M., Johnston L.J., et al. Comparison of chronic graft versus host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow up of a randomized trial. Blood 2002, 100:415-419.
12. Eapen M., Logan B., Confer D., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft versus host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
13. Anasetti C., Logan B., Lee S., et al. Peripheral blood stem cells versus bone marrow from unrelated donors. New Engl J Med 2012, 367:1487-1496.
14. Kasamon Y.L., Luznik L., Lefell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttrasplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
15. Prezepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
16. Filipovich A.H., Weisdorf D., Pavletics S., et al. National Institute of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
17. Kaplan E.L., Meier P.H. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Gooley T.A., Leisenring W., Crowley J.A., Storer B.E. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999, 18:695-706.
19. Martin P., McDonald G., Sanders J., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood and Marrow Transplant 2004, 10:320-327.
20. Hockenbery D., Cruickshank S., Rodell T., et al. A randomized, placebo-controlled trial of oral beclomethasone diproprionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
21. Grosso D., Carabasi M., Filicko-O'Hara J., et al. A two-step approach to myeloablative haploidentical stem cell transplantation: a phase I/II trial performed with optimized T cell dosing. Blood 2011, 118:4732-4739.
22. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood and Marrow Transplant 2012, 18:1859-1866.